Market Place
Sourcing Support
March Biosciences Unveils Positive Phase 2 MB-105 CD5 CAR-T
08 Dec 2025 //
GLOBENEWSWIRE
March Biosciences Names Gurpreet Ratra as Chief Business Officer
03 Dec 2025 //
GLOBENEWSWIRE
March Biosciences Granted FDA RMAT Designation For MB-105
11 Nov 2025 //
GLOBENEWSWIRE
March Biosciences Presents MB-105 Phase 2 Interim Data at ASH
03 Nov 2025 //
GLOBENEWSWIRE
March Biosciences Starts Phase 2 Trial of CD5 CAR-T for Lymphoma
22 Apr 2025 //
GLOBENEWSWIRE
March Bio FDA Orphan Drug Designation For MB-105 In T-Cell Lymphoma
28 Jan 2025 //
GLOBENEWSWIRE
March Bio Elects Peter Olagunju as Chair of Board of Directors
19 Dec 2024 //
GLOBENEWSWIRE
March Biosciences Closes $28.4M Series A Financing
23 Oct 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.